Memantina Teva

Memantine Hydrochloride, the active ingredient in Memantina, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memantina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina is a NMDA receptor antagonist used in the management of Alzheimer’s disease and its associated symptoms. - Moderate Alzheimer’s disease: improves cognition and daily functioning. - Severe Alzheimer’s disease: may help maintain basic activities of daily living. - Behavioral symptoms of Alzheimer’s disease: can reduce agitation and aggression.

Memantina may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Confusion: temporary disorientation. - Hypertension: elevated blood pressure readings. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Seizures: new‑onset convulsive episodes. - Cardiac arrhythmias: irregular heart rhythms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Suicidal thoughts: emergence of depressive ideation. - Respiratory depression: reduced breathing effort.

When prescribing Memantina, several safety considerations should be observed. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - History of seizures: use with caution and monitor neurologic status. - Concurrent use with other NMDA antagonists: avoid additive neurotoxicity. - Pregnancy and breastfeeding: safety not established; weigh potential risks and benefits. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Memantina can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity when combined. - Other NMDA antagonists: additive antagonistic effect may lead to excessive inhibition. - Strong CYP450 inducers (e.g., carbamazepine): may lower memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish the cognitive benefits of memantine. - Diuretics: can increase the likelihood of hypotension. - Antihypertensives: monitor blood pressure for additive lowering effect.